Nuvaxovid is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 12 years and older. The originally authorised Nuvaxovid contains a version of a protein found on the surface of SARS‑CoV‑2 (the virus that causes COVID-19), which has been produced in the laboratory. As SARS-CoV-2 keeps evolving, Nuvaxovid has been adapted to target the most recent strains of the virus. This helps maintain protection against COVID-19. Therefore, Nuvaxovid is also authorised as two adapted vaccines, with Nuvaxovid JN.1 being the most recent: - Nuvaxovid XBB.1.5, which contains a version of the protein from the Omicron XBB.1.5 subvariant of SARS-CoV-2; - Nuvaxovid JN.1, which contains a version of the protein from the Omicron JN.1 subvariant of SARS-CoV-2.
Therapeutic Indication
### Therapeutic indication Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations. Nuvaxovid XBB.1.5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
N/AATC Code
J07BN04
ATC Item
covid-19, protein subunit
Pharmacotherapeutic Group
Covid-19 vaccines
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| SARS CoV-2 (Original) recombinant spike protein | N/A | SARS-CoV-2 vaccine |
| SARS-CoV-2 (Omicron XBB.1.5) recombinant spike protein | N/A | XBB.1 omicron subvariant monovalent vaccine (SARS-CoV-2 infection) |
EMA Name
Nuvaxovid
Medicine Name
Nuvaxovid
Aliases
N/ANo risk management plan link.
